IL-17
We now have an absolute plethora of agents available for use in psoriatic arthritis (PsA). In contrast we have an almost complete lack of understanding of how best to optimise use of these agents –…
The ACR Convergence 2024 meeting provided its attendees with vast information about disease pathophysiology, diagnosis and treatment covering both clinical and basic sciences. One of the hot topics…
1 month ago
What is the effect of cs/bDMARDs on weight in #PsA?
⬇️Weight loss seen with:
IL17i
IL23i
csDMARDs
⬆️Weight gain seen with:
TNFi
IL12/23i
Important to consider #comorbidity & #BMI in management decisions in PsA
Ab2639 #ACR24 @RheumNow
1 month ago
A#2582 McInnes
Sonelokimab - IL17A,F nanobody
Prior P2 in PsO, HS
ARGO: P2 W24 RCT
Significant improv in ACR response
High PASI90/100 data
Up to 60% achieved MDA by W24
Improved PsAID domains (PRO)
Safety no IBD, MACE, depr. 2% oral candida
IZAR-1,2 - P3 ongoing
#ACR24 @RheumNow https://t.co/O4fEhTC8jK
1 month ago
A#2585
PsABIOnd observ cohort study of IL23 (GUS) or IL17i
6 mo interim results of 686 pts
PROs: PsAID-12
High Rx persistence at 6mo -94% on both Rx
Comparable improvement in PsAID-12 - best results skin, discomfort
1/2 with clinically meaningful improvement
#ACR24 @RheumNow https://t.co/TM1jwTRR7C
1 month ago
A#2586
EBIO study - secukinumab on entheseal bx in PsA. Compare b/l to 3+ mo on SEC
Biopsy: change of entheseal cell composition on IL-17A Rx
- decr Il-17A producing cells in responding pts
Spatial transcriptomics - colocalizarjon of ILC2, CD200+ fibroblasts
@RheumNow #ACR24 https://t.co/kMiqpBRxuE
Poster Hall